Ovarian gynandroblastoma

Summary

Ovarian gynandroblastoma (MONDO:0020540) is a disease with 1 cohort gene and 4 clinical trials. Top therapeutic interventions include paclitaxel, bleomycin sulfate, and etoposide phosphate.

At a glance

• Cohort genes: 1
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian gynandroblastoma
Mondo ID	MONDO:0020540
MeSH	C538459
Orphanet	99914
NCIT	C3072
SNOMED CT	254867003
UMLS	C0346178
MedGen	83412
GARD	0009665
Is cancer (heuristic)	no

Also known as: Gynandroblastoma · Gynandroblastoma of ovary · Gynandroblastoma of the ovary

Disease family

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › reproductive system neoplasm › sex cord-stromal tumor › ovarian sex cord-stromal tumor › ovarian gynandroblastoma

Related subtypes (5): malignant sex cord stromal tumor of ovary, ovarian sertoli-stromal cell tumor, ovarian granulosa cell tumor, benign ovarian sex cord-stromal tumor, ovarian thecoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 7 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
DICER1	Orphanet:276399	Familial multinodular goiter
DICER1	Orphanet:284343	DICER1 tumor-predisposition syndrome
DICER1	Orphanet:404476	Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome
DICER1	Orphanet:99757	Embryonal rhabdomyosarcoma
DICER1	Orphanet:99914	Gynandroblastoma
DICER1	Orphanet:99915	Malignant granulosa cell tumor of the ovary
DICER1	Orphanet:99916	Malignant Sertoli-Leydig cell tumor of the ovary

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DICER1	HGNC:17098	ENSG00000100697	Q9UPY3	Endoribonuclease Dicer	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DICER1	Endoribonuclease Dicer	Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	1	12.0×	0.083

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
DICER1	Enzyme (other)	yes	3.1.26.3	RNase_III_dom, Helicase_C-like, PAZ_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
caput epididymis	1
cauda epididymis	1
tongue squamous epithelium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DICER1	295	ubiquitous	marker	cauda epididymis, caput epididymis, tongue squamous epithelium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
DICER1	8,268

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
DICER1	Q9UPY3	21

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis	1	3806.7×	0.001	DICER1
Small interfering RNA (siRNA) biogenesis	1	1142.0×	0.002	DICER1
Regulation of MITF-M-dependent genes involved in apoptosis	1	634.4×	0.003	DICER1
MicroRNA (miRNA) biogenesis	1	456.8×	0.003	DICER1
M-decay: degradation of maternal mRNAs by maternally stored factors	1	326.3×	0.003	DICER1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of Schwann cell differentiation	1	8426.0×	0.001	DICER1
peripheral nervous system myelin formation	1	5617.3×	0.001	DICER1
global gene silencing by mRNA cleavage	1	5617.3×	0.001	DICER1
tRNA decay	1	3370.4×	0.001	DICER1
negative regulation of Schwann cell proliferation	1	2407.4×	0.001	DICER1
siRNA processing	1	1872.4×	0.002	DICER1
RISC complex assembly	1	1532.0×	0.002	DICER1
miRNA metabolic process	1	1404.3×	0.002	DICER1
apoptotic DNA fragmentation	1	1203.7×	0.002	DICER1
pre-miRNA processing	1	1123.5×	0.002	DICER1
miRNA processing	1	1053.2×	0.002	DICER1
nerve development	1	936.2×	0.002	DICER1
positive regulation of myelination	1	766.0×	0.002	DICER1
negative regulation of tumor necrosis factor-mediated signaling pathway	1	455.5×	0.003	DICER1
neuron projection morphogenesis	1	276.3×	0.004	DICER1
negative regulation of tumor necrosis factor production	1	251.5×	0.004	DICER1
negative regulation of gene expression	1	69.1×	0.015	DICER1
negative regulation of transcription by RNA polymerase II	1	17.7×	0.056	DICER1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
DICER1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
DICER1	8	Binding:8

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
DICER1	3.1.26.3	ribonuclease III

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	DICER1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DICER1	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00006227	PHASE2	COMPLETED	Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00748657	PHASE2	COMPLETED	Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
NCT01042522	PHASE2	UNKNOWN	Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT03382158	Not specified	RECRUITING	International PPB/DICER1 Registry

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACLITAXEL	4	2
BLEOMYCIN SULFATE	4	1
ETOPOSIDE PHOSPHATE	4	1